IL-10+ regulatory B lymphocytes are impacted by intradermal PBMCs therapy in patients with unexplained recurrent pregnancy loss (uRPL).

[BACKGROUND] Following the confirmation of studies on the improvement of pregnancy outcomes after treatment with lymphocytes, this project aimed to assess the effectiveness of this treatment method in patients with unexplained recurrent pregnancy loss (uRPL).

[METHODS] After isolating B cells from 100 uRPL patients, the frequency of IL-10B cells after treatment was measured by flow cytometry. Real-time PCR was applied to appraise the mRNA expression of microRNA and Programmed death-ligand 1(PD-L1) genes. The measurement of interleukin-10 (IL-10) secretory level in the supernatant medium was performed using the Enzyme-linked immunosorbent assay (ELISA) method.

[RESULTS] The data demonstrated that the frequency of IL-10B cells increased after treatment with PBMCs. The expression levels of miR-10a and miR-155 were elevated in patients who received PBMCs treatments, while the levels of miR-16 and miR-21 were decreased. Furthermore, after PBMCs treatment, an increased expression level of PD-L1 was observed. The ELISA results indicated that IL-10 secretion levels increased significantly with PBMC therapy. In the group treated with PBMCs, 33 out of 50 women (66%) achieved a live birth, compared to only 15 out of 50 women (30%) in the control group.

[CONCLUSION] In patients with uRPL, PBMCs treatment can enhance the chances of successful pregnancy by positively influencing immune regulatory factors.